Harmony Biosciences Holdings, Inc.(HRMY)Earnings, Financials & Key RatiosHarmony Biosciences Holdings, Inc. (HRMY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the significant volatility in FCF margins, ranging from 12.9% to 51.7%, warrants caution regarding the sustainability of current cash generation.
Harmony Biosciences Holdings, Inc. (HRMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Harmony Biosciences Holdings, Inc. (HRMY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.55vs $0.76-27.6% | $215Mvs $221M-2.5% |
| Q1 2026 | Feb 24, 2026 | $0.38vs $0.84-54.8% | $244Mvs $240M+1.4% |
| Q4 2025 | Nov 4, 2025 | $0.87vs $0.92-5.4% | $239Mvs $240M-0.2% |
| Q3 2025 | Aug 5, 2025 | $0.68vs $0.78-12.8% | $200Mvs $220M-8.9% |
Recent stock market news and headlines for Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
Key metrics vs top competitors for Harmony Biosciences Holdings, Inc. (HRMY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $38.26 | $2.21B | 14.12 | 21.51% | 18.27% | 20.75% | — | |
| $247.72 | $15.54B | -42.42 | 4.88% | 0.66% | 0.71% | — | |
| $12.51 | $2.65B | 83.40 | 26.93% | 10.51% | 10.2% | — | |
| $249.76 | $12.85B | -67.87 | 65.55% | -26.59% | -260.01% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — |
Harmony Biosciences Holdings, Inc. (HRMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Harmony Biosciences Holdings, Inc. (HRMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
May 7, 2026·SEC
Apr 14, 2026·SEC
Get notified when HRMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Harmony Biosciences Holdings, Inc. (HRMY) stock FAQ — growth, dividends, profitability & financials explained
Harmony Biosciences Holdings, Inc. (HRMY) reported $899.1M in revenue for fiscal year 2025.
Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 21.5% over the past year. This is strong growth.
Yes, Harmony Biosciences Holdings, Inc. (HRMY) is profitable, generating $145.6M in net income for fiscal year 2025 (18.3% net margin).
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 20.8%. This is excellent, indicating efficient use of shareholder capital.
Harmony Biosciences Holdings, Inc. (HRMY) generated $341.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
